Hepatitis B Rapid Screen Test: iCARE HBsAg Rapid Test Kit

The iCARE HBsAg Rapid Test Kit delivers an advanced Hepatitis B rapid screen test solution, providing an exceptional 99% sensitivity and 99% specificity. As a reliable point-of-care rapid diagnostic test, it is ideal for routine clinical evaluation, screening programs, and rapid diagnosis, particularly across underserved or under-resourced healthcare environments.

How to Perform the HBsAg Test Step-by-Step

To guarantee accurate diagnostic outcomes, medical staff should strictly observe the testing protocol:

  1. Immerse the Strip: Submerge the specialized diagnostic test strip directly into the prepared serum or plasma specimen.
  2. Observe Fluid Limits: Ensure the sample fluid level does not submerge past the clearly marked maximum line on the test strip.
  3. Wait for Development: Allow the qualitative immunoassay to react completely. The rapid test results must be read exactly at the 15-minute mark.

Important Result Interpretation: A weak or faint line in the test region

Hepatitis B Rapid Screen Test: 99% Sensitivity Performance

This in vitro diagnostics (IVD) kit ranks among the most sensitive clinical tools available on the market for detecting the presence of HBsAg in patient samples.

Versatile Sample Processing: Operating via an in vitro qualitative immunoassay method, this system effectively detects HBsAg in whole blood, serum, and plasma, enabling healthcare professionals to make swift, well-informed treatment and screening decisions..

Exceptional Detection Limits: It features a high analytical sensitivity of 0.1 IU/mL, making it sensitive enough to successfully identify reactivated HBsAg variants within serum samples.

Rapid Turnaround Time: The iCARE HBsAg 2 test kit supplies dependable point-of-care results within 15 minutes.

iCARE HBsAg Hepatitis B Surface Antigen Rapid Screen Test

Hepatitis B Rapid Screen Test: 99% Specificity and Accuracy

To optimize early intervention and clinical diagnosis, medical screening supplies must deliver precision that aligns with established gold standards. This kit is engineered to minimize false-positive occurrences, drastically improving access to reliable diagnosis in under-resourced regions. Clinical studies evaluating these infectious disease test kits across diverse populations and settings confirm that HBsAg kits demonstrate a higher baseline accuracy profile compared to typical HCV-Ab tests. Furthermore, this rapid diagnostic test maintains a clinical sensitivity range extending from 73% to 100%, alongside a stable Negative Predictive Value (NPV) that averages 92%. In the absence of a False Negative (FN) test result, both the Positive Predictive Value (PPV) and NPV converge perfectly to 100%. Because the baseline performance profiles of rapid medical diagnostic test kits can fluctuate between different manufacturing lines, all supplies should be carefully evaluated by laboratory managers prior to deployment in active clinical practice.

About Author:

JAL Medical Singapore
Mr. Andre Han

Managing Director, JAL Medical Singapore

Mr. Andre Han is the Managing Director of JAL Medical Singapore, a strategic subsidiary of a publicly listed biomedical manufacturer headquartered in Hsinchu, Taiwan. The parent company is internationally recognized for its ISO 13485 and GMP-certified production capabilities, delivering high-quality diagnostic solutions to global healthcare markets.
With over 20 years of experience in the medical device industry, Mr. Han brings deep expertise in commercial strategy, product development, and international market expansion. He oversees a comprehensive portfolio that includes in-vitro diagnostic test kits including STD Rapid Test Kits, HCG Pregnancy Test Kit, HIV Test Kit, Ovulation Detection Kit, Dengue Test Kits, Syphilis Test Kits, Herpes Test Kit, Chlamydia Rapid Test Kit, Gonorrhoea Test Kit, Menopause Test Kit, and proprietary blood glucose monitoring systems tailored for both clinical and home environments. Under Mr. Han’s leadership, JAL Medical has:

  • Distributed hundreds of millions of rapid diagnostic test kits globally
  • Secured long-term national tenders in South Africa
  • Expanded into key markets including Laos, Mongolia, Ghana, Kenya, Ukraine, Nigeria, and Japan
Beyond commercial operations, Mr. Han spearheads consultancy initiatives focused on:
  • Rapid test innovation and development
  • Facility optimization and regulatory alignment
  • Enhancing quality, reliability, and affordability across product lines
His strategic vision and commitment to innovation continue to position JAL Medical Singapore as a trusted provider of accessible, high-performance healthcare technologies worldwide.

Listening Article